Aurobindo Pharma dipped 4.7% to Rs 633 on BSE in late noon deal after the company said the US drug regulator issued six large procedural observations for its Unit III, a formulation manufacturing facility located at Bachupally, Hyderabad.
Leveraging on a new acquisition and its existing product pipeline that includes potential launches of molecules going off-patent in the new year, Aurobvindo Pharma Limited is aiming to double its revenues in Europe to Euro 1 billion in the next 3-5 years.
Hyderabad-based Aurobindo Pharma Limited has reported a 33.5% jump in consolidated net profit at Rs 605.64 crore for the quarter ended September 2016 on the back of higher growth in formulations business in the US market.
Aurobindo Pharma has moved higher by 4.4% to Rs 842 on the BSE after the company announced that it has received tentative approval for Dolutegravir 50mg from US Food & Drug Administration (USFDA). The drug is used for the treatment of HIV.
Aurobindo Pharma has rallied 6% to Rs 778 on the BSE in early morning trade after the company reported 24% year on year (YoY)jump in consolidated net profit at Rs 585 crore for the quarter ended June 30, 2016 (Q1FY17), on the back of higher
Indian generics pharmaceutical company Aurobindo Pharma Limited has reported a 24% increase in consolidated net profit at Rs 584.6 crore for the quarter ended June, 2016 driven by double-digit sales growth across major markets led by the US formulations
Hyderabad-based Aurobindo Pharmaceuticals is planning to raise funds via a share sale to fund the acquisition of Israel-based Teva Pharmaceutical’s European assets, if its bid is accepted by this month.
In what could boost their fortunes significantly, three Indian companies — Sun Pharma, Aurobindo Pharma and Glenmark Pharma — have received approval from the United States Food and Drug Administration (USFDA) to manufacture and market generic
In what could boost their fortunes significantly, three Indian companies - Sun Pharma, Aurobindo Pharma and Glenmark Pharma - have received approval from United States Food & Drug Administration (USFDA) to manufacture and market generic versions of
In a major development, Aurobindo Pharma announced on Wednesday that the company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market cholesterol lowering Rosuvastatin Calcium Tablets, 5 mg (base), 10 mg
Indian pharmaceutical major Aurobindo Pharma Limited, which has crossed $2 billion revenue mark in FY16, is planning to step up the momentum this year by increasing the number of launches in the US market as it aims to reach $3 billion in revenues in next